Guidelines for the treatment of nephrotic syndrome

Japanese Journal of Nephrology

Volumn 53, Issue 2, 2011, Pages 78-122

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

NEPHROTIC SYNDROME; REVIEW; TREATMENT PLANNING;

AGE FACTORS; ALBUMINS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIET, PROTEIN-RESTRICTED; DIET, SODIUM-RESTRICTED; DIURETICS; EXERCISE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; NEPHROTIC SYNDROME; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREDNISOLONE; PULSE THERAPY, DRUG;

EID: 79955417295     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (238)

1. Muller F. Korreferet. Morbus Brightii, Verhandl. Deut Path GesellMerano 1905 ; 9 : 64-99.
2. Volhard F, Fahr T. Die Brightsche Nierenkrankheit. Berlin, 1914 : 33-35.
3. Sharpstone P, Ogg CS, Cameron JS. Nephrotic syndrome due to primary renal disease in adults : II. A controlled trial of prednisolone and azathioprine. Br Med J 1969 ; 2(5656) : 535-539.
4. Shiiki H, Saito T, Nishitani Y, Mitarai T, Yorioka N, Yoshimura A, Yokoyama H, Nishi S, Tomino Y, Kurokawa K, Sakai H. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004 ; 65 : 1400-1407. (Pubitemid 38406980)
5. Report of the International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 1981 ; 98 : 561-564.
6. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int 2007 ; 72 : 1429-1447. (Pubitemid 350197945)
7. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007 ; 18 : 1899-1904. (Pubitemid 46870326)
8. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999 ; 56 : 2220-2226. (Pubitemid 30004751)
9. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy, definition and relevance of a partial remission. Kidney Int 2004 ; 66 : 1199-1205. (Pubitemid 39121029)
10. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, Mandolfo S, Messa P. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006 ; 47 : 233-240. (Pubitemid 43121326)
11. Ballarin J, Poveda R, Ara J, Pérez L, Calero F, Grinyó JM, Romero R. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil : results of a pilot study. Nephrol Dial Transplant 2007 ; 22 : 3196-3201. (Pubitemid 350202550)
12. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein : creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998 ; 316(7130) : 504-509. (Pubitemid 28120955)
13. Beatty OL, Ritchie CM, Bell PM, Hadden DR, Kennedy L, Atkinson AB. Microalbuminuria as identified by a spot morning urine specimen in non-insulin-treated diabetes : an eight-year follow-up study. Diabet Med 1995 ; 12 : 261-266.
14. Palmer BF, Alpern RJ. Pathogenesis of edema formation in the nephrotic syndrome. Kidney Int 1997 ; 59(Suppl) : S21-S27.
15. Koomans HA, Kortlandt W, Geers AB, Dorhout Mees EJ. Lowered protein content of tissue fluid in patients with the nephrotic syndrome : observations during disease and recovery. Nephron 1985 ; 40 : 391-395. (Pubitemid 15026152)
16. Dorhout Mees EJ, Geers AB, Koomans HA. Blood volume and sodium retention in the nephrotic syndrome : a controversial pathophysiological concept. Nephron 1984 ; 36 : 201-211.
17. Vande Walle JG, Donckerwolcke RA, van Isselt JW, Derkx FH, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995 ; 346 : 148-152.
18. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998 ; 338 : 1202-1211. (Pubitemid 28180750)
19. Brater DC. Diuretic therapy. N Engl J Med 1998 ; 339 : 387-395.
20. Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002 ; 13 : 798-805.
21. Fliser D, Zurbrüggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1995 ; 55 : 629-634.
22. Akcicek F, Yalniz T, Basci A, Ok E, Mees EJ. Diuretic effect of frusemide in patients with nephrotic syndrome : is it potentiated by intravenous albumin? BMJ 1995 ; 310 : 162-163.
23. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987 ; 32 : 198-203. (Pubitemid 17122984)
24. Agarwal R, Gorski JC, Sundblad K, Brater DC. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 2000 ; 11 : 1100-1105. (Pubitemid 30367940)
25. Ostermann M, Alvarez G, Sharpe MD, Martin CM. Frusemide administration in critically ill patients by continuous compared to bolus therapy. Nephron Clin Pract 2007 ; 107 : c70-76.
26. Rybak LP. Furosemide ototoxicity : clinical and experimental aspects. Laryngoscope 1985 ; 95 : 1-14.
27. Perico N, Remuzzi G. Edema of the nephrotic syndrome : the role of the atrial peptide system. Am J Kidney Dis 1993 ; 22 : 355-366. (Pubitemid 23263609)
28. Koomans HA, Geers AB, vd Meiracker AH, Roos JC, Boer P, Dorhout Mees EJ. Effects of plasma volume expansion on renal salt handling in patients with the nephrotic syndrome. Am J Nephrol 1984 ; 4 : 227-234. (Pubitemid 14058853)
29. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T. Aggravation of minimal change nephrotic syndrome by administration of human albumin. Clin Nephrol 1992 ; 37 : 109-114.
30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993 ; 329 : 1456-1462. (Pubitemid 23335891)
31. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 ; 345 : 851-860.
32. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997 ; 349 : 1857-1863.
33. Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007 ; 18 : 1959-1965.
34. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease : a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009 ; 4 : 542-551.
35. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 ; 358 : 2433-2446. (Pubitemid 351793017)
36. Grekas D, Alivanis P, Kalekou H, Syrganis C, Tourkantonis A. Are antiplatelet agents of value in the treatment of chronic glomerular disease? Nephrol Dial Transplant 1987 ; 2 : 377-379.
37. Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 2006 ; 10 : 268-273. (Pubitemid 46012956)
38. Wheeler DC. Lipid abnormalities in the nephrotic syndrome : the therapeutic role of statins. J Nephrol 2001 ; 14(Suppl 4) : S70-75.
39. van Dokkum RP, Henning RH, de Zeeuw D. Statins cholesterol, blood pressure and beyond. J Hypertens 2002 ; 20 : 2351-2353.
40. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes : a meta-analysis. J Am Soc Nephrol 2006 ; 17 : 2006-2016.
41. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pravastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010 ; 61 : 58-61.
42. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y ; K-FLAT study group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 2001 ; 89 : 408-415.
43. Muso E, Nishizawa Y, Saito T, Mune M, Hirano T, Hattori M, Yorioka N, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 2007 ; 67 : 341-344.
44. Kaysen GA, Gambertoglio J, Jimenez I, Jones H, Hutchison FN. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986 ; 29 : 572-577.
45. Maroni BJ, Staffeid C, Young VR, Manatunga A, Tom K. Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet. J Clin Invest 1997 ; 99 : 2479-2487.
46. The Merk Manuals http://www.merck.com/mmpe/index.html.
47. Poortmans JR, Vanderstraeten J. Kidney function during exercise in healthy and diseased humans. An update. Sports Med 1994 ; 18 : 419-437.
48. Miura H, Fukui H, Hayano K, Otsuka Y, Hattori S. A case of minimal change nephrotic syndrome associated with acute renal failure after excessive exercise. Nippon Jinzo Gakkai Shi 1993 ; 35 : 387-391.
49. Yan K, Kudo A, Hirano H, Watanabe T, Tasaka T, Kataoka S, Nakajima N, Nishibori Y, Shibata T, Kohsaka T, Higashihara E, Tanaka H, Watanabe H, Nagasawa T, Awa S. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int 1999 ; 56 : 65-73. (Pubitemid 29300522)
50. Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C, Grassi C, Delia Volpe M, Perfumo F, Petrone P, Picca M, et al. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br Med J (Clin Res Ed) 1985 ; 291 : 1305-1308.
51. Palmer SC, Nand K, Strippoli GF. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst Rev(1) : CD001537, 2008.
52. 2009 ; 50 : 38-42.
53. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008 ; 14 : 931-938.
54. Mathieson PW. Proteinuria and immunity - an overstated relationship? N Engl J Med 2008 ; 359 : 2492-2494.
55. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993 ; 43 : 1377-1384.
56. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 2008 Jul 16 ; (3) : CD003233.
57. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. Cyclosporine in patients with steroid-resistant membranous nephropathy : a randomized trial. Kidney Int 2001 ; 59 : 1484-1490.
58. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006 ; 21 : 3127-3132. (Pubitemid 44567084)
59. Shirai S, Yasuda T, Tsuchida H, Kuboshima S, Konno Y, Shima Y, Sato T, Hatta S, Masuhara K, Kimura K. Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. Clin Exp Nephrol 2009 ; 13 : 123-129.
60. Kusaba T, Konno Y, Hatta S, Fujino T, Yasuda T, Miura H, Sasaki H, Okabayashi J, Murao M, Sakurada T, Imai G, Shirai S, Kuboshima S, Shima Y, Ogimoto G, Sato T, Masuhara K, Kimura K. More stable and reliable pharmacokinetics with preprandial administration of cyclosporine compared with postprandial administration in patients with refractory nephrotic syndrome. Pharmacotherapy 2005 ; 25 : 52-58.
61. Takeda A, Horike K, Onoda H, Ohtsuka Y, Yoshida A, Uchida K, Morozumi K. Benefits of cyclosporine absorption profiling in nephrotic syndrome : preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. Nephrology 2007 ; 12 : 197-204. (Pubitemid 46426861)
62. Tang S, Tang AW, Tam MK, Ho YW. Use of tacrolimus in steroid-and cyclophosphamide-resistant minimal change nephrotic syndrome. Am J Kidney Dis 2003 ; 42 : E13-15.
63. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C ; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003 ; 349 : 36-44. (Pubitemid 36765101)
64. Doi T, Masaki T, Shiraki N, Kawai T, Yorioka N. Oral mizoribine pulse therapy for steroid-dependent focal segmental glomerulosclerosis. Clin Nephrol 2008 ; 69 : 433-435. (Pubitemid 351803484)
65. Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, Shiiki H, Makino H, Sato H, Ishikawa I, Maeda K, Tomita K, Arakawa M, Ishida M, Sato M, Nagase M, Kashihara N, Yorioka N, Koike T, Saito T, Harada T, Mitarai T, Sugisaki T, Nagasawa T, Tomino Y, Nojima Y, Kobayashi Y, Sakai O. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol 2004 ; 8 : 117-126. (Pubitemid 38899638)
66. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002 ; 61 : 1098-1114. (Pubitemid 34175479)
67. Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 2009 ; 5 : 132-142.
68. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995 ; 25 : 862-875.
69. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001 ; 135 : 248-257.
70. Imai H, Kodama T, Yasuda T, Nakamoto Y, Miura AB. Inverse relationship between serum Cholinesterase activity and the administration of cyclophosphamide : an index of cyclophosphamide therapy. Nephrol Dial Transplant 1994 ; 9 : 1240-1249. (Pubitemid 24283648)
71. Cox R, Goorha S, Irving CC. Inhibition of DNA methylase activity by acrolein. Carcinogenesis 1988 ; 9 : 463-465. (Pubitemid 18067966)
72. Bryant BM, Jarman M, Ford HT, Smith IE. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980 ; 2(8196) : 657-659. (Pubitemid 10048650)
73. Vose JM, Reed EC, Pippert GC, Anderson JR, Bierman PJ, Kessinger A, Spinolo J, Armitage JO. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation : a randomized trial. J Clin Oncol 1993 ; 11 : 1306-1310. (Pubitemid 23199134)
74. (Guideline for Management of Vasculitis Syndrome, JCS 2008). Circulation Journal 2008 ; 72(SupplIV) : 1254-1310.
75. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008 ; 3 : 1652-1659.
76. Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, Moriyama T, Sugiura H, Tsukada M, Takei T, Ogawa T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 2009 ; 72 : 69-72.
77. Hofstra JM, Deegens JK, Wetzels JF. Rituximab : effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant 2007 ; 22 : 2100-2102.
78. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-1305.
79. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993 ; 44 : 638-642. (Pubitemid 23265235)
80. Fried LF, Orchard TJ, Kasiske BL ; for the Lipids and Renal Disease Progression Meta-analysis Study Group. Effect of lipid reduction on the progression of renal disease : a metanalysis. Kidney Int 2001 ; 59 : 260-269. (Pubitemid 32055234)
81. Tonelli M, Moyé L, Sacks F, Cole T, Curham G. Effect of pravastatin on loss of renal function in patients with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003 ; 14 : 1605-1613. (Pubitemid 36687063)
82. Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 2004 ; 62 : 245-259. (Pubitemid 39386800)
83. Yashiro M, Muso E, Shio H, Sasayama S. Amelioration of hypercholesterolaemia by HMG-CoA reductase inhibitor (Pravastatin) improved platelet hyperaggregability in nephrotic patients. Nephrol Dial Transplant 1994 ; 9 : 1842-1843.
84. Rayner BL, Byrne MJ, van Zyl Smit R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 1996 ; 46 : 219-224. (Pubitemid 26385555)
85. Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002 ; 62 : 550-555.
86. Ogi M, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Takaeda M, Wada T, Naito T, Ikeda K, Goshima S, Takasawa K, Kobayashi K. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 1994 ; 24 : 427-436. (Pubitemid 24277939)
87. Taube D, Chapman S, Brown Z, Williams DG. Depression of normal lymphocyte transformation by sera of patients with minimal change nephropathy and other forms of nephrotic syndrome. Clin Nephrol 1981 ; 15 : 286-290. (Pubitemid 11064842)
88. Centers for Disease Control and Prevention. Preventing pneumococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997 ; 46(RR-8) : 1-24.
89. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000 ; 49(RR-9) : 1-35.
90. Cisneros JM, Muñoz P, Torre-Cisneros J, Gurgui M, Rodriguez-Hernandez MJ, Aguado JM, Echaniz A. Pneumonia after heart transplantation : a multi-institutional study. Spanish Transplantation Infection Study Group. Clin Infect Dis 1998 ; 27 : 324-331.
91. Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 2004 ; 128 : 1023-1027.
92. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust 1995 ; 162 : 233-235.
93. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 ; 71 : 5-13. (Pubitemid 26021784)
94. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-2498.
95. Saito K, Nakayamada S, Nakano K, Tokunaga M, Tsujimura S, Nakatsuka K, Adachi T, Tanaka Y. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases : re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology 2004 ; 43 : 479-485. (Pubitemid 38489366)
96. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 ; 17 : 770-782. (Pubitemid 39372516)
97. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002 ; 34 : 1098-1107. (Pubitemid 34289683)
98. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985 ; 28 : 429-439. (Pubitemid 15248032)
99. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis : acute and chronic. Am J Med 1980 ; 69 : 819-827. (Pubitemid 11199851)
100. Cherng SC, Huang WS, Wang YF, Yang SP, Lin YF. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med 2000 ; 25 : 167-172.
101. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome : a clinical conundrum. J Am Soc Nephrol 2007 ; 18 : 2221-2225. (Pubitemid 47203835)
102. Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med 2008 ; 121 : 226-230. (Pubitemid 351317912)
103. Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome : results from a large retrospective cohort study. Circulation 2008 ; 117 : 224-230.
104. Wass VJ, Jarrett RJ, Chilvers C, Cameron JS. Does the nephrotic syndrome increase the risk of cardiovascular disease? Lancet 1979 ; 2 : 664-667.
105. Sarasin FP, Schifferli JA. Prophylatic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994 ; 45 : 578-585. (Pubitemid 24065096)
106. Bramham K, Hunt BJ, Goldsmith D. Thrombophilia of nephrotic syndrome in adults. Clin Adv Hematol Oncol 2009 ; 7 : 368-372.
107. Ganeval D, Fischer AM, Barre J, Pertuiset N, Dautzenberg MD, Jungers P, Houin G. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol 1986 ; 25 : 75-80. (Pubitemid 16156332)
108. Al-Momen AK, Al-Abdul-Kareem H. Potentiation of the action of warfarin by bezafibrate in patients with the nephrotic syndrome. Saudi J Kidney Dis Transplant 1994 ; 5 : 12-16.
109. Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben Maadi A, Jazaerli N, Radier C, Rahmouni A, Mathieu D, Vasile N, Rosso J, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron 1995 ; 69 : 20-28.
110. Lee JC, Yamauchi H, Hopper J Jr. The association of cancer and the nephrotic syndrome. Ann Intern Med 1966 ; 64 : 41-51.
111. Row PG, Cameron JS, Turner DR, Evans DJ, White RH, Ogg CS, Chantier C, Brown CB. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med 1975 ; 44 : 207-239.
112. Cahen R, Francois B, Trolliet P, Gilly J, Parchoux B. Aetiology of membranous glomerulonephritis : a prospective study of 82 adult patients. Nephrol Dial Transplant 1989 ; 4 : 757-758.
113. Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 2003 ; 23 : 400-405. (Pubitemid 37022044)
114. Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis 1993 ; 22 : 5-10.
115. Zeng CH, Chen HM, Wang RS, Chen Y, Zhang SH, Liu L, Li LS, Liu ZH. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis 2008 ; 52 : 691-698.
116. Kramer P, Sizoo W, Twiss EE. Nephrotic syndrome in Hodgkin's disease. Report of five cases and review of the literature. Neth J Med 1981 ; 24 : 114-119. (Pubitemid 11036997)
117. Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delirier A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma : report of 21 cases and review of the literature. Kidney Int 2006 ; 69 : 2251-2260.
118. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis : risks and relation to cyclophosphamide. Ann Rheum Dis 2004 ; 63 : 1307-1311.
119. Queille S, Luron L, Spatz A, Avril MF, Ribrag V, Duvillard P, Hiesse C, Sarasin A, Armand JP, Daya-Grosjean L. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis 2007 ; 28 : 724-731. (Pubitemid 46523370)
120. Lewis EJ, Busch GJ, Schur PH. Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases. J Clin Invest 1970 ; 49 : 1103-1113.
121. Doi T, Mayumi M, Kanatsu K, Suehiro F, Hamashima Y. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol 1984 ; 58 : 57-62. (Pubitemid 14029124)
122. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 1997 ; 51 : 270-276. (Pubitemid 27064546)
123. Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int 2005 ; 68 : 302-310. (Pubitemid 43181389)
124. Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, Kigawa A, Sawada K, Imai H. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004 ; 19 : 574-579. (Pubitemid 38263115)
125. Andreucci M, Federico S, Andreucci VE. Edema and acute renal failure. Semin Nephrol 2001 ; 21 : 251-256.
126. Koomans HA. Pathophysiology of acute renal failure in idiopathic nephrotic syndrome. Nephrol Dial Transplant 2001 ; 16 : 221-224. (Pubitemid 32123905)
127. Mandal AK, Baig M, Koutoubi Z. Management of acute renal failure in the elderly. Treatment options. Drugs Aging 1996 ; 9 : 226-250. (Pubitemid 26345710)
128. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 2002 ; 62 : 2223-2229. (Pubitemid 35366179)
129. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ 2008 ; 336 : 1185-1189. (Pubitemid 351809281)
130. Research Group on Progressive Chronic Renal Disease. Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Nephron 1999 ; 82 : 205-213.
131. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal change nephrotic syndrome in adults : response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991 ; 17 : 687-692.
132. Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002 ; 39 : 503-512. (Pubitemid 34194626)
133. Takei T, Koike M, Suzuki K, Shirota S, Itabashi M, Ohtsubo S, Sugiura H, Suzuki K, Kojima C, Takahashi M, Ino J, Ogawa T, Uchida K, Tsuchiya K, Yumura W, Nitta K. The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clin Exp Nephrol 2007 ; 11 : 214-217. (Pubitemid 47476793)
134. Nachman PH, Jennette JC, Falk RJ. Primary glomerular diseases. In : Brenner BM (ed) Brenner & Rector's the kidney 8th ed, Philadelphia : Saunders Elsevier, 2008 : 995-1000.
135. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal-change disease : clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007 ; 2 : 445-453.
136. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome : a long-term follow-up. Kidney Int 1986 ; 29 : 1215-1223.
137. Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970 ; 3 : 421-426.
138. Coggins CH. Adult minimal change nephropathy : experience of the collaborative study of glomerular disease. Trans Am Clin Climatol Assoc 1986 ; 97 : 18-26.
139. Tse KC, Lam MF, Yip PS, Li FK, Choy BY, Lai KN, Chan TM. Idiopathic minimal change nephrotic syndrome in older adults : steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 2003 ; 18 : 1316-1320.
140. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Lancet 1988 ; 1 (8582) : 380-383.
141. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 1993 ; 152 : 357-361. (Pubitemid 23094416)
142. Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 1996; 11 : 2192-2201. (Pubitemid 26385914)
143. Matsumoto H, Nakao T, Okada T, Nagaoka Y, Takeguchi F, Tomaru R, Iwasawa H. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Intern Med 2004 ; 43 : 668-673. (Pubitemid 39264164)
144. Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis : a multicenter study in Korea. Clin Nephrol 1995 ; 43 : 375-381.
145. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zarcchello G, Confalonieri R, Altieri P, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome : a multicentre randomized controlled trial. Nephrol Dial Transplant 1993 ; 8 : 1326-1332. (Pubitemid 24038066)
146. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A : minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991 ; 35(Suppl) : S37-S42.
147. Cade R, Mars D, Privette M, Thompson R, Croker B, Peterson J, Campbell K. Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Arch Intern Med 1986 ; 146 : 737-741.
148. Buemi M, Nostra L, Crascì E, Barillà A, Cosentini V, Aloisi C, Sofi T, Campo S, Frisina N. Statins in nephrotic syndrome : a new weapon against tissue injury. Med Res Rev 2005 ; 25 : 587-609. (Pubitemid 41447525)
149. Gheith OA, Sobh MA, Mohamed Kel-S, El-Baz MA, El-Husseini F, Gazarin SS, Ahmed HA, Rasem MW, Amer GM. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002 ; 91 : 612-619. (Pubitemid 34914061)
150. Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome : non-specific strategies for treatment. Nephrology (Carlton)2008 ; 13 : 45-50.
151. D'Agati VD, Fogo A, Bruijn J, Jennette JC. Pathological classification of focal segmental glomerulosclerosis : a working proposal. Am J Kidney Dis 2004 ; 43 : 368-382. (Pubitemid 38146337)
152. D'Agati VD. Podocyte injury in focal segmental glomerulosclerosis : Lessons from animal models. Kidney Int 2008 ; 73 : 399-406. (Pubitemid 351186280)
153. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005 ; 308(5729) : 1801-1804. (Pubitemid 40848011)
154. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden BW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008 ; 40 : 1175-1184.
155. Sekine T, Konno M, Sasaki S, Moritani S, Miura T, Wong WS, Nishio H, Nishiguchi T, Ohuchi MY, Tsuchiya S, Matsuyama T, Kanegane H, Ida K, Miura K, Hattori M, Horita S, Igarashi T, Saito H, Kunishima S. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int 2010 ; 78 : 207-214.
156. Marszal J, Saleem MA. The bioactivity of plasma factors in focal segmental glomerulosclerosis. Nephron Exp Nephrol 2006 ; 104 : e1-e5.
157. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. Clin Nephrol 1991 ; 36 : 53-59.
158. Agarwal SK, Dash SC, Tiwari SC, Bhuyan UN. Idiopathic adult focal segmental glomerulosclerosis : a clinicopathological study and response to steroid. Nephron 1993 ; 63 : 168-171.
159. Rydell JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults : presentation, course, and response to treatment. Am J Kidney Dis 1995 ; 25 : 534-542.
160. Ponticelli C, Villa M, Banfi G, Cesana B, Pozzi C, Pani A, Passerini P, Farina M, Grassi C, Baroli A. Can prolonged treatment improve the prognosis of adults with FSGS? Am J Kidney Dis 1999 ; 34 : 618-625.
161. Matalon A, Valeri A, Appel GB. Treatment of focal segmental glomerulosclerosis. Semin Nephrol 2000 ; 20 : 309-317. (Pubitemid 30327440)
162. Korbet SM. The treatment of primary focal segmental glomerulosclerosis. Ren Fail 2000 ; 22 : 685-696.
163. Korbet SM. Treatment of primary focal and segmental glomerulosclerosis. Kidney Int 2002 ; 62 : 2301-2310. (Pubitemid 35366191)
164. Hari P, Bagga A, Jidani N, Srivastava RN. Treatment of focal glomrulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 2001 ; 16 : 901-905. (Pubitemid 33040650)
165. Kirpekar R, Yorgin PD, Tune BM, Kim MK, Sibley RK. Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. Am J Kidney Dis 2002 ; 39 : 1143-1152. (Pubitemid 34591928)
166. Chang JW, Yang LY, Wang HH. Low-dose methylprednisolone pulse therapy in Chinese children with steroid resistant focal segmental glomerulosclerosis. Pediatr Int 2007 ; 49 : 349-354.
167. Pena A, Bravo J, Melgosa M, Fernandez C, Meseguer C, Espinosa L, Alonso A, Picazo ML, Navarro M. Steroid-resistant nephrotic syndrome, long-term evolution after sequential therapy. Pediatr Nephrol 2007 ; 22 : 1875-1880. (Pubitemid 47506227)
168. Heering P, Braun N, Mullejans R, Ivens K, Zauner I, Funfstuck R, Keller F, Kramer BK, Schollmeyer P, Risler T, Grabensee B ; German Collaborative Glomerulonephritis Study Group. Cyclosporin A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004 ; 43 : 10-18.
169. Meyrier A. Treatment of focal segmental glomerulosclerosis with immunophilin modulation : when did we stop thinking about pathogenesis? Kidney Int 2009 ; 76 : 487-491.
170. Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. Expert Opin Pharmacother 2009 ; 10 : 615-628.
171. Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Yata N, Kaneko T, Honda M ; Japanese Study Group of Renal Disease. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2009 ; 24 : 2177-2185.
172. Tanaka H, Oki E, Tsuruga K, Sato N, Matsunaga A, Kondo Y, Suzuki J. Mizoribine treatment of young patients with severe lupus nephritis : a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract 2008 ; 110 : c73-79.
173. Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis. Jpn J Nephrol 1988 ; 30 : 1153-1160.
174. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, MatsunagaA, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003 ; 42 : 1121-1130. (Pubitemid 37486754)
175. Kida H, Asamoto T, Yokoyama H, Tomosugi N, Hattori N. Long-term prognosis of membranous nephropathy. Clin Nephrol 1986 ; 25 : 64-69. (Pubitemid 16156330)
176. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Sem Nehrol 2003 ; 23 : 324-332. (Pubitemid 37022035)
177. Bazzi C, Petrini C, Rizza V, Arrigo G, D'Amico G. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 2000 ; 58 : 1732-1741.
178. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009 ; 361 : 11-21.
179. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G. Prognosis and untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993 ; 329 : 85-89. (Pubitemid 23188821)
180. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M ; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010 ; 21 : 697-704.
181. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998 ; 9 : 444-450. (Pubitemid 28122870)
182. Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapy and future intervention for treatment of membranous nephropathy. Sem Nephrol 2003 ; 23 : 362-372. (Pubitemid 37022039)
183. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity : long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000 ; 35 (3 Suppl 1) : S7-11.
184. West CD. Childhood membranoproliferative glomerulonephritis : an approach to management. Kidney Int 1986 ; 29 : 1077-1093. (Pubitemid 16122581)
185. Cameron JS, Turner DR, Heaton J, Williams DG, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983 ; 74 : 175-192. (Pubitemid 13192172)
186. Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int 1995 ; 47 : 643-656.
187. Neary JJ, Conlon PJ, Croke D, Dorman A, Keogan M, Zhang FY, Vance JM, Pericak-Vance MA, Scott WK, Winn MP. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol 2002 ; 13 : 2052-2057. (Pubitemid 34790781)
188. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Men S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Würzner R, Zipfel PF. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007 ; 18 : 2447-2456.
189. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993 ; 328 : 465-470.
190. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999 ; 106 : 347-354.
191. Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis : influence of therapy. Kidney Int 1989 ; 35 : 1227-1233.
192. Yamabe H, Johnson RJ, Gretch DR, Osawa H, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995 ; 6 : 220-223.
193. Nasr SH, Markowitz GS, Stokes MB, Seshan SV, Valderrama E, Appel GB, Aucouturier P, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits : a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004 ; 65 : 85-96. (Pubitemid 38037493)
194. Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, Nadasdy T, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009 ; 20 : 2055-2064.
195. Masai R, Wakui H, Togashi M, Maki N, Ohtani H, Komatsuda A, Sawada K. Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol 2009 ; 71 : 9-20.
196. Ahmed M, Solangi K, Abbi R, Adler S. Nephrotic syndrome, renal failure, and renal malignancy : an unusual tumor-associated glomerulonephritis. J Am Soc Nephrol 1997 ; 8 : 848-852.
197. Suzuki J, Suzuki S, Nozawa R, Kawasaki Y, Suzuki H. Membranoproliferative glomerulonephritis associated with hereditary deficiency of the 4th component of complement. Clin Nephrol 2003 ; 60 : 279-283. (Pubitemid 37258853)
198. Kamar N, Rostaing L, Alric L. Treatment of hepatic C-virus-related glomerulonephritis. Kideny Int 2006 ; 69 : 436-439. (Pubitemid 43164433)
199. Donadio JV Jr, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 1989 ; 14 : 445-451. (Pubitemid 20057890)
200. Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006 ; 69 : 504-511. (Pubitemid 43164442)
201. Tarshish P, Bernstein J, Tobin JN, Edelmann CM, Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone - a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992 ; 6 : 123-130.
202. Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I : limited steroid therapy. Kidney Int 1992 ; 41 : 1606-1612.
203. Zauner I, Bohler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis : a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol Dial Transplant 1994 ; 9 : 619-622.
204. Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 2004 ; 19 : 3160-3164. (Pubitemid 40057644)
205. Arneil GC. 164 children with nephrosis. Lancet 1961 ; 18 : 1103-1110.
206. Cattran D. Management of membranous nephropathy : when and what for treatment. J Am Soc Nephrol 2005 ; 16 : 1188-1194. (Pubitemid 41716503)